MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of allogeneic invariant natural killer T (iNKT) cell therapies. The company's pipeline includes both native and engineered iNKT programs, designed for scalable and reproducible manufacturing to enable off-the-shelf delivery. MiNK's lead product candidate, agenT-797, is an allogeneic, native iNKT cell therapy being evaluated in clinical trials for its potential in treating solid tumors and immune-mediated diseases. Additionally, the company is developing engineered iNKT programs, such as MiNK-413 and MiNK-215, targeting specific antigens associated with cancer. MiNK's approach aims to harness the properties of iNKT cells to address unmet medical needs in oncology and immunology.
Tech Stack (2 technologies)
Frequently Asked Questions
What technologies does MiNK Therapeutics use?+
MiNK Therapeutics uses 2 technologies including Google Font API, Nginx.
What industry is MiNK Therapeutics in?+
MiNK Therapeutics operates in the Biopharma industry.
Where is MiNK Therapeutics based?+
MiNK Therapeutics is headquartered in United States.
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026